Approval · Notice of Compliance 17816 · 2016
ULORIC: Notice of Compliance 17816
Issued February 29, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17816
- Date
- February 29, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph regarding the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), toxic epidermal necrolysis and cardiac failure.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ULORIC | Not yet assigned | — |
Medicinal ingredients
- FEBUXOSTAT 80 MG per TAB